Sotagliflozin is in clinical development for the treatment of type 2 diabetes mellitus (T2DM). T2DM is a common, lifelong condition that causes the level of glucose in the blood to become too high. It is caused by problems with a chemical in the body (hormone) called insulin, which is produced in the pancreas and is responsible for controlling the amount of glucose in the blood. There are two main types of diabetes: type 1 – where the pancreas does not produce any insulin, and type 2 – where the pancreas does not produce enough insulin or body cells do not react to insulin.
Sotagliflozin is one of a new class of drugs that increase elimination of glucose in the urine. They offer the advantages of a reduced risk of low blood sugar. Sotagliflozin reduces the reabsorption of glucose from the intestines and kidneys, thus improving blood glucose control in diabetes mellitus. If licensed, sotagliflozin will offer an additional treatment option for patients with T2DM.
Liraglutide acts like a hormone the body produces naturally that regulates appetite, known as glucagon-like-peptide (GLP-1). By activating areas of the brain that regulate appetite, liraglutide may decrease feelings of hunger which can lead to lower calorie intake and weight loss. If licensed, liraglutide may improve long-term outcomes for weight management in obese adolescents 12-17 years old who currently have limited treatment options.